TareBio
TareBio is a YC Summer 2026 (S26) company. Based in San Francisco, CA, USA. Team of 1.
About TareBio
Summary
TareBio develops a vaccine platform that produces personalized or population-level vaccines against cancer and infectious disease in weeks. Rather than predicting which antigens to target upfront, the platform samples immune cells already fighting a disease in the patient's body and reverse-engineers the antigens that activate them. This approach replaces years of conventional antigen-discovery work with a single swappable input, the immune imprint, and has already produced a vaccine that cleared cancer in mice.
From the Y Combinator listing
Vaccines for any cancer or infection in weeks.
Our platform develops personalized or population-level vaccines for any disease in weeks by changing only one input: the immune imprint. Instead of trying to predict which antigens might work, we read out immune cells already fighting the disease in the body and reverse-engineer antigens that activate them. We've already run our platform end-to-end and created a vaccine that cured cancer in mice.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- San Francisco, CA, USA
- 1
- Active
- Early
Founders (1)
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works